Loading data for TCRT — first visit, this takes a few seconds.
Alaunos Therapeutics, Inc.
1.49 -0.02 (-1.32%)
- Рыночная капитализация
- $3.79M
- Объём торгов
- 9.51K
- Следующая дата отчётности
- Aug 14, 2025
Alaunos Therapeutics, Inc. (TCRT): цена акции, анализ и данные
Внутренняя стоимость
Прогноз аналитиков
Прогнозы по акции →Последние результаты
| Отчитано | К прогнозу | Изменение г/г | |
|---|---|---|---|
| Выручка | $0 | n/a | n/a |
| EPS | -$17,09 | -$12,59 | -184.83% |
Метрики
- Бид
- 1.24
- Рыночная капитализация
- 3.79M
- Чистая прибыль (TTM)
- -4.12M
- -0.97
- -1.75
- n/a
- -2.48
- P/B (TTM)
- 2.75
- P/S (TTM)
- 1261.77
- Дата отчёта
- Aug 14, 2025
- Аск
- 1.7
- Объём торгов
- 9,512
- Ср. объём (20д)
- 12,327
- Открытие
- 1.49
- Пред. закрытие
- 1.51
- Диапазон дня
- 1.49 - 1.53
- Диапазон за 52 недели
- 1.49 - 4.59
- Аналитики
- n/a
- Целевая цена
- n/a
- Дивиденды
- n/a
- Дата отсечки
- n/a
О компании Alaunos Therapeutics, Inc.
Профиль →Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
Отрасль Biotechnology
Сектор Healthcare
Дата IPO Aug 24, 2005
Сотрудники 1
Биржа NasdaqCM
Тикер TCRT